International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064


Downloads: 1 | Views: 50 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Analysis Study Research Paper | Pharmacy | India | Volume 13 Issue 2, February 2024


Methanolic Extract of Terminalia Arjuna Seeeds against Anticoagulant Activity

Payyaula Naresh [4] | Noulla Saraswathi | Chakali Vijaya Laxmi | Gade Sandyarani [2]


Abstract: In an environment that predominately favours an anticoagulant state, coagulation inculdes the controlled proteolytic activation of a number of zymogens in order to produce suitable and prompt hemostasis in a damaged vessel. The inciting event in the non - pathological state involves the exposure of circulating factor VII/VIIa to extravascularly expressed tissue factor, sets in motion a series of events that amplifies the initial stimulus and leads to the conversion of fibrinogen to fibrin and clot formation. A set of anticogulant processes balances the well timed chain of events and ensures that the haemostatic effect is controlled and does not go too far. In contrast, due to inherited or acquired abnormalities, these processes may escape normal regulatory systems in diseased situations. That result in thrombosis. Despite being based on drugs that have been around for more than 80 years, current anticoagulant therapy is shifting towards targeted therapy for particular coagulation factors and events in the coagulation cascade due to the current understanding of the primary triggers and crucial events within the series of reactions that results in haemostasis. In an environment that predominately favours an anticoagulant state, coagulation inculdes the controlled proteolytic activation of a number of zymogens in order to produce suitable and prompt hemostasis in a damaged vessel. The inciting event in the non - pathological state involves the exposure of circulating factor VII/VIIa to extravascularly expressed tissue factor, sets in motion a series of events that amplifies the initial stimulus and leads to the conversion of fibrinogen to fibrin and clot formation. A set of anticogulant processes balances the well timed chain of events and ensures that the haemostatic effect is controlled and does not go too far. In contrast, due to inherited or acquired abnormalities, these processes may escape normal regulatory systems in diseased situations. That result in thrombosis. Despite being based on drugs that have been around for more than 80 years, current anticoagulant therapy is shifting towards targeted therapy for particular coagulation factors and events in the coagulation cascade due to the current understanding of the primary triggers and crucial events within the series of reactions that results in haemostasis.


Keywords: Terminalia arjuna, EDTA, Coagulation factors, Rivaroxaban, Megakaryocytes, Ticlopidine, Clopidogrel, Ticagrelor and Prasugrel.


Edition: Volume 13 Issue 2, February 2024,


Pages: 1211 - 1213


How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link


Verification Code will appear in 2 Seconds ... Wait

Top